Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Galinpepimut-S Plus Nivolumab Provides Survival Benefits With Acceptable Safety in Mesothelioma

June 28th 2023

The combination of galinpepimut-S and nivolumab provided positive survival outcomes with an acceptable safety profile in patients with malignant pleural mesothelioma who were refractory to or relapsed after at least 1 line of standard treatment.

Practical Considerations Regarding the Incorporation of Supportive Care Into Practice

June 28th 2023

Jorge Nieva, MD, and Ashish Saxena, MD, PhD, consider the broader impact of supportive care on cost burden and quality of life and share scenarios in which supportive care is most appropriate.

Quality of Life and Patient-Reported Outcome Measures in SCLC Treatment

June 28th 2023

Jorge Nieva, MD, and Ashish Saxena, MD, PhD, share insights about the value of patient-reported outcomes studies and the extent to which they can shape treatment decisions.

Dr Murray on the Investigation of Prognostic Markers in Cemiplimab-treated NSCLC

June 27th 2023

Joseph Christopher Murray, MD, PhD, discusses the investigation of peripheral myeloid cells as prognostic markers in patients with non–small cell lung cancer treated with cemiplimab.

Examining LIFU–Aided Liquid Biopsy in Glioblastoma: Raising the Bar With the LIMITLESS Trial

June 27th 2023

In this fourth episode of OncChats: Examining LIFU–Aided Liquid Biopsy in Glioblastoma, Manmeet Singh Ahluwalia, MD, MBA, FASCO, and Michael W. McDermott, MD, discuss the key objectives of the phase 3 LIMITLESS study (NCT05317858) examining low-intensity focused ultrasound with immunotherapy and chemotherapy in patients with lung cancer and brain metastases.

Dr Oselin on a Subgroup Analysis of the PEARLS/KEYNOTE-091 Trial in NSCLC

June 26th 2023

Kersti Oselin, MD, PhD, discusses a subgroup analysis from the phase 3 PEARLS/KEYNOTE-091 study of pembrolizumab in patients with early-stage non‒small-cell lung cancer following resection.

Camidge and Cetnar Revisit ASCO 2023 Data in Lung Cancer

June 26th 2023

In this episode of ‘How This is Building Me,’ Dr Camidge is rejoined by Dr Cetnar to discuss the good, the bad, and the ugly of the lung cancer data that were presented at the 2023 ASCO Annual Meeting.

Impact of Disease Staging on Prognosis and Treatment in SCLC

June 26th 2023

Panel experts review disease staging for limited and extensive stage small-cell lung cancer and discuss the impact of staging on treatment selection.

Importance of Early Referral and Diagnosis in Small-Cell Lung Cancer

June 26th 2023

Expert oncologists provide an overview of the landscape surrounding small-cell lung cancer and highlight the importance of early referral and diagnosis for overall patient outcomes.

Dr Wermke on the Investigation of BI 764532 in DLL3+ SCLC and NEC

June 23rd 2023

Martin Wermke, MD, discusses the investigation of BI 764532 in patients with DLL3-positive small cell lung cancer and neuroendocrine carcinoma.

Selecting Optimal Treatment in Early-Stage NSCLC

June 23rd 2023

Ben Levy, MD offers insight into how he approaches the selection of the optimal treatment strategy in early-stage non-small cell lung cancer.

Overview of Early-Stage NSCLC and Molecular Testing

June 23rd 2023

A panel of experts who treat patients with non-small cell lung cancer provides an overview of staging, molecular testing and treatment options in stage I-IIIB non-small cell lung cancer.

The Role of Supportive Care in the Management of Myelosuppression in Patients With SCLC

June 21st 2023

Jorge Nieva, MD, and Ashish Saxena, MD, PhD, talk about factors to consider when weighing the risk/benefit ratio associated with the use of cyclin-dependent kinase 4/6 inhibition.

Challenges in the Management of Patients With SCLC

June 21st 2023

Jorge Nieva, MD, and Ashish Saxena, MD, PhD, discuss the impact of chemotherapy-induced myelosuppression on patients with SCLC.

Dr Nassar on Treatment Options After Chemoradiation in Unresectable, Stage III, EGFR-Mutated NSCLC

June 20th 2023

Amin Nassar, MD, discusses findings from a retrospective study of the use of EGFR TKI therapy, durvalumab, or observation following concurrent chemoradiation in patients with unresectable, stage III non–small cell lung cancer harboring EGFR mutations.

Reuss Reviews the Development of LP-300 in Advanced NSCLC

June 19th 2023

Dr Reuss discusses the development of LP-300 in advanced NSCLC, the mechanisms of LP-300 that may help synergize with the activity of platinum-based chemotherapy, and its ongoing investigation in the phase 2 HARMONIC trial.

Exploring TROP2 Expression in Patients with NSCLC

June 16th 2023

Martin Dietrich, MD, PhD, and Wade Thomas Iams, MD, review the value of TROP2 as a target in patients with NSCLC.

Targeting HER3 in EGFR-Mutant NSCLC

June 16th 2023

Experts review data on treatment with HER3-directed agents in NSCLC for patients with EGFR mutations.

Persistence Is Key to Success

June 15th 2023

Vinay Edlukudige Keshava, MD, shares the story of his fellowship and provides advice on how to best transition to the next step in an oncologic career.

FDA Approves New Drug Application for Oncology Injectable Pemrydi RTU

June 14th 2023

The FDA has approved a 505(b)(2) new drug application for Pemrydi RTU, the first and only ready-to-use presentation of pemetrexed or injection that does not require reconstitution, dilution, or refrigeration